Tuesday, 20 Nov 2018

You are here

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.

In this cohort there were a total of 51,150 recorded deaths.  All cause mortality was significantly increased in:

  • exclusive current cigarette smokers (HR 1.98; 95% CI, 1.93-2.02)
  • exclusive current cigar smokers (HR, 1.20; 95% CI, 1.03-1.38)

A significantly increased risk of tobacco-related cancer deaths (bladder, esophagus, larynx, lung, oral cavity, and pancreas CA) was seen in:

  • exclusive current cigarette smokers (HR, 4.06; 95% CI, 3.84-4.29)
  • exclusive current cigar smokers (HR, 1.61; 95% CI, 1.11-2.32)
  • exclusive current pipe smokers (HR, 1.58; 95% CI, 1.05-2.38)

For nondaily cigarette users, statistically significant associations were seen for deaths from:

  • lung cancer (HR, 6.24; 95% CI, 5.17-7.54),
  • oral cancer (HR, 4.62; 95% CI, 1.84-11.58),
  • circulatory death (HR, 1.43; 95% CI, 1.30-1.57),
  • cardiovascular death (HR, 1.24; 95% CI, 1.11-1.39),
  • cerebrovascular death (stroke) (HR, 1.39; 95% CI, 1.12-1.74),
  • COPD (HR, 7.66; 95% CI, 6.09-9.64) as well as for daily smokers.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Musculoskeletal Events with Statin Use

Analysis of the FDA Adverse Event Reporting System data examined the association between statins' musculoskeletal adverse events (MAEs).

Review of the data shows that atorvastatin and rosuvastatin (with strong low‐density lipoprotein cholesterol‐lowering effects) had a higher risk and a faster onset of MAEs when compared with simvastatin.

They could not detect whether concomitant drugs shifted the onset timing of MAEs. 

Low Short-Term Risks of NSAIDs in High Risk Patients

JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-37 days of exposure). 

Update on Checkpoint Inhibitor Safety

“Autoimmunity is the Achilles heel of onco-immunotherapy” per Dr. Leonard Calabrese, which leaves a dilemma for rheumatologists. Onco-immunotherapy induces immune dysregulation to allow patients to develop an immune response to their cancer cells. An unfortunate side effect for patients taking onco-immunotherapy is often autoimmune-like diseases referred to as immune adverse reactions (irAEs). Studies in France and the United States have shown that irAEs can be a good prognostic sign, suggesting these therapies are working. Rheumatology is faced with new problems as onco-immunotherapies may induce new chronic diseases in multiple different forms secondary to the treatment.

Anti-phospholipid Antibodies and Myocardial Infarction.

The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal Medicine reports.

Update on Immune Checkpoint Inhibitor Toxicity

JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.